Systematic review of the role of alternative application routes for opioid treatment for moderate to severe cancer pain: An EPCRC opioid guidelines project

被引:42
作者
Radbruch, Lukas [1 ,2 ]
Trottenberg, Peter [3 ]
Elsner, Frank [3 ]
Kaasa, Stein [4 ]
Caraceni, Augusto [5 ]
机构
[1] Univ Bonn, Dept Palliat Med, D-5300 Bonn, Germany
[2] Malteser Hosp Bonn, Ctr Palliat Med, Bonn, Germany
[3] Rhein Westfal TH Aachen, Dept Palliat Med, Aachen, Germany
[4] Norwegian Univ Sci & Technol, N-7034 Trondheim, Norway
[5] Natl Canc Inst, Dept Palliat Med, I-20133 Milan, Italy
关键词
Neoplasm; pain; opioids; CONTINUOUS SUBCUTANEOUS INFUSION; PATIENT-CONTROLLED ANALGESIA; TRANSMUCOSAL FENTANYL CITRATE; RELEASE ORAL MORPHINE; HIGH-DOSE OPIOIDS; TRANSDERMAL BUPRENORPHINE; DOUBLE-BLIND; OPEN-LABEL; INTRAVENOUS FENTANYL; PHASE-III;
D O I
10.1177/0269216310383739
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The European Palliative Care Research Collaboration is updating the EAPC recommendations on opioids in cancer pain management. A systematic literature search on Medline on the use of alternative routes for opioid application identified 242 papers, with 72 publications included in the final evaluation. Two or more alternative routes of opioid application were compared in 18 papers with a total of 674 patients. The best evidence base was available for the subcutaneous route. A comparison of subcutaneous and intravenous routes found no differences, confirming both routes as feasible, effective and safe. Efficacy and safety of the rectal route was comparable to the parenteral route. The side effect profile seemed to be very similar for the subcutaneous, intravenous, rectal or transdermal routes. Local side effects were reported for rectal application as well as for subcutaneous and transdermal administration. In conclusion, the systematic review found good evidence that subcutaneous administration of morphine or other opioids is an effective alternative for cancer patients if oral treatment is not possible. However, for a number of patients intravenous, rectal or transdermal therapy will offer a good alternative to the subcutaneous route. The review found no significant differences in efficacy or side effects between the alternative application routes.
引用
收藏
页码:578 / 596
页数:19
相关论文
共 64 条
[31]   Symptom assessment in palliative care: A need for international collaboration [J].
Kaasa, Stein ;
Loge, Jon Havard ;
Fayers, Peter ;
Caraceni, Augusto ;
Strasser, Florian ;
Hjermstad, Marianne Jensen ;
Higginson, Irene ;
Radbruch, Lukas ;
Haugen, Dagny Faksvag .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (23) :3867-3873
[32]   Epidural and subcutaneous morphine in the management of cancer pain: A double-blind cross-over study [J].
Kalso, E ;
Heiskanen, T ;
Rantio, M ;
Rosenberg, PH ;
Vainio, A .
PAIN, 1996, 67 (2-3) :443-449
[33]   CONTINUOUS NARCOTIC INFUSION WITH PATIENT-CONTROLLED ANALGESIA FOR CHRONIC CANCER PAIN IN OUTPATIENTS [J].
KERR, IG ;
SONE, M ;
DEANGELIS, C ;
ISCOE, N ;
MACKENZIE, R ;
SCHUELLER, T .
ANNALS OF INTERNAL MEDICINE, 1988, 108 (04) :554-557
[34]   A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain [J].
Kornick, CA ;
Santiago-Palma, J ;
Schulman, G ;
O'Brien, PC ;
Weigand, S ;
Payne, R ;
Manfredi, PL .
CANCER, 2003, 97 (12) :3121-3124
[35]  
Kornick CA, 2001, CANCER, V92, P3056, DOI 10.1002/1097-0142(20011215)92:12<3056::AID-CNCR10166>3.0.CO
[36]  
2-H
[37]   Continuous Morphine Infusions for Cancer Pain in Resource-Scarce Environments: Comparison of the Subcutaneous and Intravenous Routes of Administration [J].
Koshy, Rachel C. ;
Kuriakose, Renju ;
Sebastian, Paul ;
Koshy, Cherian .
JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2005, 19 (01) :27-33
[38]   Morphine use for at-home cancer patients in Japan [J].
Kotani, K .
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 204 (02) :119-123
[39]   Efficacy and Tolerability of Intranasal Fentanyl Spray 50 to 200 μg for Breakthrough Pain in Patients With Cancer: A Phase III, Multinational, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial With a 10-Month, Open-Label Extension Treatment Period [J].
Kress, Hans Georg ;
Oronska, Anna ;
Kaczmarek, Zbigniew ;
Kaasa, Stein ;
Colberg, Torben ;
Nolte, Thomas .
CLINICAL THERAPEUTICS, 2009, 31 (06) :1177-1191
[40]  
LANG AH, 1991, RECENT RES CANCER, V121, P51